<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104389">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02152761</url>
  </required_header>
  <id_info>
    <org_study_id>CBYM338D2201</org_study_id>
    <nct_id>NCT02152761</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery</brief_title>
  <official_title>56-week, Randomized, Multicenter, Double Blind, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Argentina: Ministry of Health</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Taiwan: Center for Drug Evaluation</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if bimagrumab is safe and effective in patients with
      muscle wasting (atrophy) after hip fracture surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in total lean body mass measured by DXA at week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 24 in total lean body mass</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in gait speed at week 24 and week 52</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 24 and from baseline to Week 52 in gait speed (meters/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in short physical performance battery at week 24 and week 52</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 24 and from baseline to Week 52 in physical performance as measured by the Short Physical Performance Battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of bimagrumab assessed by various measures such as adverse events</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and Tolerability assessed by various measures such as adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total lean body mass measured by DXA at week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 52 in total lean body mass</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Muscle Wasting (Atrophy) After Hip Fracture Surgery</condition>
  <arm_group>
    <arm_group_label>bimagrumab high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimagrumab low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the bimagrumab low dose administered via intravenous infusion starting Day 1 until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will receive matching placebo administered via intravenous infusion starting Day 1 until Week 52</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimagrumab</intervention_name>
    <description>Bimagrumab will be administered as intravenous infusion starting on Day 1 until week 52.</description>
    <arm_group_label>bimagrumab high dose</arm_group_label>
    <arm_group_label>bimagrumab low dose</arm_group_label>
    <other_name>BYM338</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo will be administered as intravenous infusion starting on Day 1 until week 52.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have X-ray confirmed successful hip fracture repair;

          -  must have completed surgical wound healing;

          -  ability to walk a specified distance with or without a walking aid;

          -  must weigh at least 35 kg.

        Exclusion Criteria:

          -  Must not have history of fracture of the same hip;

          -  Must not have history of any other lower limb fractures in the past 6 months;

          -  Must meet cardiovascular requirements; Must not have a chronic active infection (e.g.
             HIV, hepatitis B or C, etc);

          -  Must not have used high-dose corticosteroid medications for at least 3 months in the
             past year;

          -  Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kamakura-city</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto-city</city>
        <state>Kumamoto</state>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Japan</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bimagrumab</keyword>
  <keyword>BYM338</keyword>
  <keyword>hip fracture</keyword>
  <keyword>elderly</keyword>
  <keyword>controlled clinical trial</keyword>
  <keyword>randomized</keyword>
  <keyword>muscle wasting</keyword>
  <keyword>atrophy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
